Bolt Biotherapeutics, Inc.
BOLTNasdaqCIK 1641281HealthcareFiscal year ends Dec 31
Reports and events: 90 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2310:31 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-429647 |
| 2026-10-0616:07 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-26-415560 |
| 2026-08-1116:06 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-344597 |
| 2026-08-1116:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344580 |
| 2026-06-1116:05 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-267487 |
| 2026-05-1216:06 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-219382 |
| 2026-05-1216:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-219361 |
| 2026-04-2816:05 ET | DEF 14A | Proxy statementPeriod 2026-04-27 | 0001193125-26-186923 |
| 2026-03-1216:07 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-104121 |
| 2026-03-1216:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-104102 |
| 2026-02-2619:22 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001012975-26-000212 |
| 2026-02-1720:11 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001012975-26-000173 |
| 2025-11-1216:08 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-277549 |
| 2025-11-1216:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-277521 |
| 2025-10-0216:05 ET | 8-K | 2.05 Exit or disposal costs; 8.01 Other events | 0001193125-25-228293 |
| 2025-08-1416:09 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001641281-25-000007 |
| 2025-08-1416:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001641281-25-000006 |
| 2025-06-0616:39 ET | 8-K | 3.01 Delisting notice; 5.03 Amendment to articles or bylaws | 0000950170-25-083180 |
| 2025-06-0416:05 ET | 8-K | 8.01 Other events | 0000950170-25-081607 |
| 2025-05-2817:41 ET | 8-K | 5.07 Shareholder vote results | 0000950170-25-077880 |
| 2025-05-1216:08 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-069188 |
| 2025-05-1216:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-069153 |
| 2025-04-2515:48 ET | DEF 14A | Proxy statementPeriod 2025-05-27 | 0000950170-25-058632 |
| 2025-04-1617:22 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0000950170-25-054871 |
| 2025-04-1516:39 ET | DEF 14A | Proxy statementPeriod 2025-05-27 | 0000950170-25-054294 |
| 2025-03-2416:26 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-043873 |
| 2025-03-2416:25 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-043869 |
| 2025-01-0316:10 ET | 8-K | 3.01 Delisting notice | 0000950170-25-001159 |
| 2024-12-2316:10 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-24-139580 |
| 2024-11-1216:14 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-125413 |
| 2024-11-1216:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-125376 |
| 2024-09-0417:38 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-24-213225 |
| 2024-08-1316:10 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-096200 |
| 2024-08-1316:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-096191 |
| 2024-07-0317:19 ET | 8-K | 3.01 Delisting notice | 0001193125-24-175113 |
| 2024-06-1413:15 ET | 8-K | 5.07 Shareholder vote results | 0000950170-24-073501 |
| 2024-05-1416:14 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-059564 |
| 2024-05-1416:06 ET | 8-K | 2.01 Completion of an acquisition or disposition; 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-24-059524 |
| 2024-04-2616:06 ET | DEF 14A | Proxy statementPeriod 2024-06-12 | 0000950170-24-049095 |
| 2024-03-2116:10 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-034692 |
| 2024-03-2116:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-034688 |
| 2024-02-1221:41 ET | SC 13D/A | Ownership report, active investor, amended | 0001193125-24-032572 |
| 2023-11-0916:10 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-062048 |
| 2023-11-0916:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-062027 |
| 2023-08-0716:08 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000950170-23-039061 |
| 2023-08-0716:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-039047 |
| 2023-06-1316:55 ET | 8-K | 5.07 Shareholder vote results | 0000950170-23-027743 |
| 2023-05-1116:11 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0000950170-23-021233 |
| 2023-05-1116:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-021225 |
| 2023-04-2816:09 ET | DEF 14A | Proxy statementPeriod 2023-06-12 | 0000950170-23-015790 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 27, 2026, 17:22 ET. Listed shows no prices and gives no investment advice.